These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31315958)

  • 21. Susceptibility testing challenges with ceftaroline, MRSA and a 1 mg/L breakpoint.
    Livermore DM; Mushtaq S; Warner M; James D; Woodford N
    J Antimicrob Chemother; 2015 Dec; 70(12):3259-66. PubMed ID: 26318188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Etest and broth microdilution for evaluating the susceptibility of Staphylococcus aureus and Streptococcus pneumoniae to ceftaroline and of carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa to ceftazidime/avibactam.
    Huang YT; Kuo YW; Teng LJ; Liao CH; Hsueh PR
    J Glob Antimicrob Resist; 2021 Sep; 26():301-307. PubMed ID: 34303027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolates Collected in 2012 from Latin American Countries as Part of the AWARE Surveillance Program.
    Biedenbach DJ; Hoban DJ; Reiszner E; Lahiri SD; Alm RA; Sahm DF; Bouchillon SK; Ambler JE
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7873-7. PubMed ID: 26416860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009-13).
    Sader HS; Farrell DJ; Flamm RK; Jones RN
    J Antimicrob Chemother; 2015 Jul; 70(7):2053-6. PubMed ID: 25814163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014.
    Pfaller MA; Mendes RE; Castanheira M; Flamm RK; Jones RN; Sader HS
    Pediatr Infect Dis J; 2017 May; 36(5):486-491. PubMed ID: 28403050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Susceptibility of clinical isolates of meticillin-resistant Staphylococcus aureus and phenotypic non-extended-spectrum β-lactamase-producing Klebsiella pneumoniae to ceftaroline in Taiwan: Results from Antimicrobial Testing Leadership and Surveillance (ATLAS) in 2012-2018 and Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2018-2019.
    Jean SS; Ko WC; Hsueh PR;
    Int J Antimicrob Agents; 2020 Jul; 56(1):106016. PubMed ID: 32422316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emergence of SCCmec type III with variable antimicrobial resistance profiles and spa types among methicillin-resistant Staphylococcus aureus isolated from healthcare- and community-acquired infections in the west of Iran.
    Mohammadi S; Sekawi Z; Monjezi A; Maleki MH; Soroush S; Sadeghifard N; Pakzad I; Azizi-Jalilian F; Emaneini M; Asadollahi K; Pourahmad F; Zarrilli R; Taherikalani M
    Int J Infect Dis; 2014 Aug; 25():152-8. PubMed ID: 24909489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growing Resistance to Vancomycin among Methicillin Resistant Staphylococcus Aureus Isolates from Different Clinical Samples.
    Pahadi PC; Shrestha UT; Adhikari N; Shah PK; Amatya R
    JNMA J Nepal Med Assoc; 2014; 52(196):977-81. PubMed ID: 26982895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Missense mutations in PBP2A Affecting ceftaroline susceptibility detected in epidemic hospital-acquired methicillin-resistant Staphylococcus aureus clonotypes ST228 and ST247 in Western Switzerland archived since 1998.
    Kelley WL; Jousselin A; Barras C; Lelong E; Renzoni A
    Antimicrob Agents Chemother; 2015 Apr; 59(4):1922-30. PubMed ID: 25583724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of ceftaroline against mecC-positive MRSA isolates.
    Armengol-Porta M; Tenorio-Abreu A; Bandt D; Coleman DC; Gavier-Widen D; Hotzel H; Kinnevey P; Lazaris A; Peters M; Rangstrup-Christensen L; Schlotter K; Shore AC; Ehricht R; Monecke S
    J Glob Antimicrob Resist; 2016 Jun; 5():3-6. PubMed ID: 27436457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluating the antibacterial activity of ceftaroline against clinical isolates of methicillin-susceptible and- resistant Staphylococcus aureus in Kuwait hospitals.
    Alfouzan W; Boswihi SS; Dhar R; Udo E
    J Infect Public Health; 2020 Oct; 13(10):1589-1591. PubMed ID: 32859552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multi-center and multi-method evaluation of in vitro activities of ceftaroline against S. aureus.
    Koeth LM; Apfalter P; Becker K; Gesu G; Martínez-Martínez L; Lahiri SD; Alm RA; Ambler J; Iaconis J
    Diagn Microbiol Infect Dis; 2016 Aug; 85(4):452-8. PubMed ID: 27233426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model.
    Singh R; Almutairi M; Alm RA; Lahiri SD; San Martin M; Chen A; Ambler JE
    J Antimicrob Chemother; 2017 Oct; 72(10):2796-2803. PubMed ID: 29091195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multicenter evaluation of the Etest and disk diffusion methods for differentiating daptomycin-susceptible from non-daptomycin-susceptible Staphylococcus aureus isolates.
    Jevitt LA; Thorne GM; Traczewski MM; Jones RN; McGowan JE; Tenover FC; Brown SD
    J Clin Microbiol; 2006 Sep; 44(9):3098-104. PubMed ID: 16954233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular characteristics of community-acquired methicillin-resistant Staphylococcus aureus in Hokkaido, northern main island of Japan: identification of sequence types 6 and 59 Panton-Valentine leucocidin-positive community-acquired methicillin-resistant Staphylococcus aureus.
    Kawaguchiya M; Urushibara N; Kuwahara O; Ito M; Mise K; Kobayashi N
    Microb Drug Resist; 2011 Jun; 17(2):241-50. PubMed ID: 21395449
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model.
    Zhanel GG; Rossnagel E; Nichol K; Cox L; Karlowsky JA; Zelenitsky S; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2011 Jun; 66(6):1301-5. PubMed ID: 21429940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [In vitro activity of ceftaroline against Spanish isolates of Staphylococcus aureus: a multicenter study].
    Tenorio-Abreu A; Gil Tomás J; Bratos Pérez MÁ; de la Iglesia Salgado A; Borrás Máñez M; Ortiz de Lejarazu Leonardo R; Ávila Alonso A; Colomina Rodríguez J; Pérez Cáceres JA; Saavedra Martín JM; Márquez Sanabria A; Domínguez Castaño A; de la Iglesia Salgado M
    Enferm Infecc Microbiol Clin; 2015 Feb; 33(2):101-4. PubMed ID: 25091384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence and genotypic relatedness of methicillin resistant Staphylococcus aureus in a tertiary care hospital.
    Fomda BA; Thokar MA; Bashir G; Khan A; Kour A; Zahoor D; Ray P
    J Postgrad Med; 2014; 60(4):386-9. PubMed ID: 25370547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A 12-year survey of methicillin-resistant Staphylococcus aureus infections in Greece: ST80-IV epidemic?
    Drougka E; Foka A; Liakopoulos A; Doudoulakakis A; Jelastopulu E; Chini V; Spiliopoulou A; Levidiotou S; Panagea T; Vogiatzi A; Lebessi E; Petinaki E; Spiliopoulou I
    Clin Microbiol Infect; 2014 Nov; 20(11):O796-803. PubMed ID: 24750462
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Pfaller MA; Sader HS; Rhomberg PR; Flamm RK; Mendes RE
    Microb Drug Resist; 2019; 25(6):938-943. PubMed ID: 30694735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.